Systemic enhancement of papaverine transdermal gel for erectile dysfunction

References

• Beckman TJ, Abu-Lebdeh HS, Mynderse LA. (2006). Evaluation and medical management of erectile dysfunction. Mayo Clin Proc, 81:385–390.
   PubMed Web of Science ®Google Scholar
• Melman A, Davies K. (2010). Gene therapy for erectile dysfunction: What is the future? Curr Urol Rep, 11:421–426.
   PubMedGoogle Scholar
• Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J et al.; EAU. (2006). EAU Guidelines on erectile dysfunction: An update. Eur Urol, 49:806–815.
   PubMed Web of Science ®Google Scholar
• Gazzaruso C. (2006). Erectile dysfunction and coronary atherothrombosis in diabetic patients: Pathophysiology, clinical features and treatment. Expert Rev Cardiovasc Ther, 4:173–180.
   PubMedGoogle Scholar
• Uckert S, Mayer ME, Stief CG, Jonas U. (2007). The future of the oral pharmacotherapy of male erectile dysfunction: Things to come. Expert Opin Emerg Drugs, 12:219–228.
   PubMed Web of Science ®Google Scholar
• Chiang HS, Kao YH, Sheu MT. (1995). Papaverine and prostaglandin E1 gel applications for impotence. Ann Acad Med Singap, 24:767–769.
   PubMedGoogle Scholar
• Kim ED, el-Rashidy R, McVary KT. (1995). Papaverine topical gel for treatment of erectile dysfunction. J Urol, 153:361–365.
   PubMed Web of Science ®Google Scholar
• Lewis RW. (2000). Intraurethral and topical agents. Drugs Today, 36:113–119.
   PubMed Web of Science ®Google Scholar
• Chiang HS, Cho SL, Lin YC, Hwang TI. (2009). Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: Evaluation by IIEF score. Urology, 73:762–766.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Payton TR, Schechter PJ. (2001). A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology, 57:301–305.
   PubMed Web of Science ®Google Scholar
• Ale I, Lachapelle JM, Maibach HI. (2009). Skin tolerability associated with transdermal drug delivery systems: An overview. Adv Ther, 26:920–935.
   PubMed Web of Science ®Google Scholar
• Heather AEB. (2005). Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv, 2:23–33.
   PubMedGoogle Scholar
• Bialik W, Walters KA, Brain KR, Hadgraft J. (1991). The effect of vehicles on the skin penetration of ibuprofen. In: Scott RC, Guy RH, Hadgraft J, Boddé HE, eds. Prediction of percutaneous penetration, Vol. 2. London: IBC, 458–464.
   Google Scholar
• Roy SD, Hou SY, Witham SL, Flynn GL. (1994). Transdermal delivery of narcotic analgesics: Comparative metabolism and permeability of human cadaver skin and hairless mouse skin. J Pharm Sci, 83:1723–1728.
   PubMed Web of Science ®Google Scholar
• Oakley DM, Swarbrick J. (1987). Effects of ionization on the percutaneous absorption of drugs: Partitioning of nicotine into organic liquids and hydrated stratum corneum. J Pharm Sci, 76:866–871.
   PubMed Web of Science ®Google Scholar
• Tojo K, Chiang CC, Chien YW. (1986). Influence of donor solution upon skin permeation of drug, J Chem Eng, 19:153–155.
   Web of Science ®Google Scholar
• Hayton WL, Chen T. (1982). Correction of perfusate concentration for sample removal. J Pharm Sci, 71:820–821.
   PubMed Web of Science ®Google Scholar
• Bronaugh RL, Stewart RF, Simon M. (1986). Methods for in vitro percutaneous absorption studies. VII: Use of excised human skin. J Pharm Sci, 75:1094–1097.
   PubMed Web of Science ®Google Scholar
• Knutson K, Krill SC, Lambert WJ, Higuchi WI. (1987). Physicochemical aspects of transdermal permeation. J Control Release, 6:59–74.
   Google Scholar
• Kayali I, Suhey T, Friberg SE, Simion FA, Rhein LD. (1995). Lyotropic liquid crystals and the structural lipids of the stratum corneum. J Pharm Sci, 84:144–149.
   Google Scholar
• El Maghraby GM, Alanazi FK, Alsarra IA. (2009). Transdermal delivery of tadalafil. I. Effect of vehicles on skin permeation. Drug Dev Ind Pharm, 35:329–336.
   PubMed Web of Science ®Google Scholar
• Kadir R, Stempler D, Liron Z, Cohen S. (1987). Delivery of theophylline into excised human skin from alkanoic acid solutions: A “push-pull” mechanism. J Pharm Sci, 76:774–779.
   PubMed Web of Science ®Google Scholar
• Berner B, Juang RH, Mazzenga GC. (1989). Ethanol and water sorption into stratum corneum and model systems. J Pharm Sci, 78:472–476.
   PubMed Web of Science ®Google Scholar
• Asbill CS, Michniak BB. (2000). Percutaneous penetration enhancers: Local versus transdermal activity. Pharm Sci Technol Today, 3:36–41.
   PubMedGoogle Scholar
• Dimas DA, Dallas PP, Rekkas DM. (2004). Ion pair formation as a possible mechanism for the enhancement effect of lauric acid on the transdermal permeation of ondansetron. Pharm Dev Technol, 9:311–320.
   PubMed Web of Science ®Google Scholar
• Yamashita F, Hashida M. (2003). Mechanistic and empirical modeling of skin permeation of drugs. Adv Drug Deliv Rev, 55:1185–1199.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. (2011). Role of novel terpenes in transcutaneous permeation of valsartan: Effectiveness and mechanism of action. Drug Dev Ind Pharm, 37:583–596.
   PubMed Web of Science ®Google Scholar
• Walters KA. (1990). Surfactants and percutaneous absorption. In: Scott RC, Guy RH, Hadgraft J, eds. Prediction of percutaneous penetration. London: IBC, 148–162.
   Google Scholar
• Ganem-Quintanar A, Lafforgue C, Falson-Rieg F, Buri P. (1997). Evaluation of transepidermal permeation of diethylene glycol monoethyl ether and skin water loss. J. Control Release, 147, 165–171.
   Google Scholar